APO Research
Talk to an analyst

APO RESEARCH · REPORT

Peptide Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Peptide Vaccine Market Outlook and Growth Opportunities 2026

30 December 2025200 pages

Choose your research edition.

Industry ResearchPeptide Vaccine Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Peptide Vaccine Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Peptide Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Peptide Vaccine Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Peptide Vaccine Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

The global Peptide Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Peptide Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Peptide Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Peptide Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Peptide Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Peptide Vaccine market include Anergis, Antigen Express, Apitope Technology, Artificial Cell Technologies, Benovus Bio, Celgene Corporation, Immatics biotechnologies, ImmunoCellular Therapeutics and ISA Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Peptide Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Peptide Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Peptide Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Peptide Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Peptide Vaccine Segment by Company

Anergis

Antigen Express

Apitope Technology

Artificial Cell Technologies

Benovus Bio

Celgene Corporation

Immatics biotechnologies

ImmunoCellular Therapeutics

ISA Pharmaceuticals

Lytix Biopharma

OncoTherapy Science

Peptech

Pharmasyntez

Spotlight Innovation

Sumitomo Dainippon Pharma

TapImmune

Targovax

Merck

Peptide Vaccine Segment by Type

Solution Phase Synthesis (SPS)

Solid Phase Peptide Synthesis (SPPS)

Peptide Vaccine Segment by Application

Pancreatic Cancer

Gastric Cancer

Breast Cancer

Prostate Cancer

Lung Cancer

Others

Peptide Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Peptide Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Peptide Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Peptide Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Peptide Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Peptide Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Peptide Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Peptide Vaccine industry.

Chapter 3: Detailed analysis of Peptide Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Peptide Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Peptide Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Peptide Vaccine Industry Trends Table 2. Peptide Vaccine Industry Drivers Table 3. Peptide Vaccine Industry Opportunities and Challenges Table 4. Peptide Vaccine Industry Restraints Table 5. Global Peptide Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Peptide Vaccine Revenue Share by Company (2021-2026) Table 7. Global Peptide Vaccine Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Peptide Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Peptide Vaccine Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Peptide Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Peptide Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Peptide Vaccine Company, Product Type & Application Table 13. Global Peptide Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Peptide Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Solution Phase Synthesis (SPS) Table 18. Significant Companies of Solid Phase Peptide Synthesis (SPPS) Table 19. Global Peptide Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Peptide Vaccine Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Peptide Vaccine Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Peptide Vaccine Sales Volume Share by Type (2021-2026) Table 23. Global Peptide Vaccine Sales Volume Share by Type (2027-2032) Table 24. Global Peptide Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Peptide Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Peptide Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Peptide Vaccine Sales Value Share by Type (2021-2026) Table 28. Global Peptide Vaccine Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Pancreatic Cancer Table 30. Significant Companies of Gastric Cancer Table 31. Significant Companies of Breast Cancer Table 32. Significant Companies of Prostate Cancer Table 33. Significant Companies of Lung Cancer Table 34. Significant Companies of Others Table 35. Global Peptide Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Peptide Vaccine Sales Volume by Application (2021-2026) & (K Units) Table 37. Global Peptide Vaccine Sales Volume by Application (2027-2032) & (K Units) Table 38. Global Peptide Vaccine Sales Volume Share by Application (2021-2026) Table 39. Global Peptide Vaccine Sales Volume Share by Application (2027-2032) Table 40. Global Peptide Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Peptide Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Peptide Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Peptide Vaccine Sales Value Share by Application (2021-2026) Table 44. Global Peptide Vaccine Sales Value Share by Application (2027-2032) Table 45. Global Peptide Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Peptide Vaccine Sales by Region (2021-2026) & (K Units) Table 47. Global Peptide Vaccine Sales Market Share by Region (2021-2026) Table 48. Global Peptide Vaccine Sales by Region (2027-2032) & (K Units) Table 49. Global Peptide Vaccine Sales Market Share by Region (2027-2032) Table 50. Global Peptide Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Peptide Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Peptide Vaccine Sales Value Share by Region (2021-2026) Table 53. Global Peptide Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Peptide Vaccine Sales Value Share by Region (2027-2032) Table 55. Global Peptide Vaccine Market Average Price (US$/Unit) by Region (2021-2026) Table 56. Global Peptide Vaccine Market Average Price (US$/Unit) by Region (2027-2032) Table 57. Global Peptide Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Global Peptide Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Peptide Vaccine Sales by Country (2021-2026) & (K Units) Table 60. Global Peptide Vaccine Sales Market Share by Country (2021-2026) Table 61. Global Peptide Vaccine Sales by Country (2027-2032) & (K Units) Table 62. Global Peptide Vaccine Sales Market Share by Country (2027-2032) Table 63. Global Peptide Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Peptide Vaccine Sales Value Market Share by Country (2021-2026) Table 65. Global Peptide Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Peptide Vaccine Sales Value Market Share by Country (2027-2032) Table 67. Anergis Company Information Table 68. Anergis Business Overview Table 69. Anergis Peptide Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Anergis Peptide Vaccine Product Portfolio Table 71. Anergis Recent Development Table 72. Antigen Express Company Information Table 73. Antigen Express Business Overview Table 74. Antigen Express Peptide Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Antigen Express Peptide Vaccine Product Portfolio Table 76. Antigen Express Recent Development Table 77. Apitope Technology Company Information Table 78. Apitope Technology Business Overview Table 79. Apitope Technology Peptide Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Apitope Technology Peptide Vaccine Product Portfolio Table 81. Apitope Technology Recent Development Table 82. Artificial Cell Technologies Company Information Table 83. Artificial Cell Technologies Business Overview Table 84. Artificial Cell Technologies Peptide Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Artificial Cell Technologies Peptide Vaccine Product Portfolio Table 86. Artificial Cell Technologies Recent Development Table 87. Benovus Bio Company Information Table 88. Benovus Bio Business Overview Table 89. Benovus Bio Peptide Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Benovus Bio Peptide Vaccine Product Portfolio Table 91. Benovus Bio Recent Development Table 92. Celgene Corporation Company Information Table 93. Celgene Corporation Business Overview Table 94. Celgene Corporation Peptide Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Celgene Corporation Peptide Vaccine Product Portfolio Table 96. Celgene Corporation Recent Development Table 97. Immatics biotechnologies Company Information Table 98. Immatics biotechnologies Business Overview Table 99. Immatics biotechnologies Peptide Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Immatics biotechnologies Peptide Vaccine Product Portfolio Table 101. Immatics biotechnologies Recent Development Table 102. ImmunoCellular Therapeutics Company Information Table 103. ImmunoCellular Therapeutics Business Overview Table 104. ImmunoCellular Therapeutics Peptide Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. ImmunoCellular Therapeutics Peptide Vaccine Product Portfolio Table 106. ImmunoCellular Therapeutics Recent Development Table 107. ISA Pharmaceuticals Company Information Table 108. ISA Pharmaceuticals Business Overview Table 109. ISA Pharmaceuticals Peptide Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. ISA Pharmaceuticals Peptide Vaccine Product Portfolio Table 111. ISA Pharmaceuticals Recent Development Table 112. Lytix Biopharma Company Information Table 113. Lytix Biopharma Business Overview Table 114. Lytix Biopharma Peptide Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Lytix Biopharma Peptide Vaccine Product Portfolio Table 116. Lytix Biopharma Recent Development Table 117. OncoTherapy Science Company Information Table 118. OncoTherapy Science Business Overview Table 119. OncoTherapy Science Peptide Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. OncoTherapy Science Peptide Vaccine Product Portfolio Table 121. OncoTherapy Science Recent Development Table 122. Peptech Company Information Table 123. Peptech Business Overview Table 124. Peptech Peptide Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Peptech Peptide Vaccine Product Portfolio Table 126. Peptech Recent Development Table 127. Pharmasyntez Company Information Table 128. Pharmasyntez Business Overview Table 129. Pharmasyntez Peptide Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. Pharmasyntez Peptide Vaccine Product Portfolio Table 131. Pharmasyntez Recent Development Table 132. Spotlight Innovation Company Information Table 133. Spotlight Innovation Business Overview Table 134. Spotlight Innovation Peptide Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. Spotlight Innovation Peptide Vaccine Product Portfolio Table 136. Spotlight Innovation Recent Development Table 137. Sumitomo Dainippon Pharma Company Information Table 138. Sumitomo Dainippon Pharma Business Overview Table 139. Sumitomo Dainippon Pharma Peptide Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 140. Sumitomo Dainippon Pharma Peptide Vaccine Product Portfolio Table 141. Sumitomo Dainippon Pharma Recent Development Table 142. TapImmune Company Information Table 143. TapImmune Business Overview Table 144. TapImmune Peptide Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 145. TapImmune Peptide Vaccine Product Portfolio Table 146. TapImmune Recent Development Table 147. Targovax Company Information Table 148. Targovax Business Overview Table 149. Targovax Peptide Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 150. Targovax Peptide Vaccine Product Portfolio Table 151. Targovax Recent Development Table 152. Merck Company Information Table 153. Merck Business Overview Table 154. Merck Peptide Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 155. Merck Peptide Vaccine Product Portfolio Table 156. Merck Recent Development Table 157. Key Raw Materials Table 158. Raw Materials Key Suppliers Table 159. Peptide Vaccine Distributors List Table 160. Peptide Vaccine Customers List Table 161. Research Programs/Design for This Report Table 162. Authors List of This Report Table 163. Secondary Sources Table 164. Primary Sources List of Figures Figure 1. Peptide Vaccine Product Image Figure 2. Global Peptide Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Peptide Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Peptide Vaccine Sales (2021-2032) & (K Units) Figure 5. Global Peptide Vaccine Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Peptide Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Solution Phase Synthesis (SPS) Image Figure 10. Solid Phase Peptide Synthesis (SPPS) Image Figure 11. Global Peptide Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Peptide Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Peptide Vaccine Sales Volume Share by Type (2021-2032) Figure 14. Global Peptide Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Peptide Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Peptide Vaccine Sales Value Share by Type (2021-2032) Figure 17. Pancreatic Cancer Image Figure 18. Gastric Cancer Image Figure 19. Breast Cancer Image Figure 20. Prostate Cancer Image Figure 21. Lung Cancer Image Figure 22. Others Image Figure 23. Global Peptide Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Peptide Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Peptide Vaccine Sales Volume Share by Application (2021-2032) Figure 26. Global Peptide Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Peptide Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Peptide Vaccine Sales Value Share by Application (2021-2032) Figure 29. Global Peptide Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 30. Global Peptide Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Peptide Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Peptide Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Peptide Vaccine Sales Value (2021-2032) & (US$ Million) Figure 34. North America Peptide Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Peptide Vaccine Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Peptide Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Peptide Vaccine Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Peptide Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Peptide Vaccine Sales Value (2021-2032) & (US$ Million) Figure 40. South America Peptide Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Peptide Vaccine Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Peptide Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Peptide Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Peptide Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Peptide Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Peptide Vaccine Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Peptide Vaccine Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Solution Phase Synthesis (SPS)
  • Solid Phase Peptide Synthesis (SPPS)
Applications
  • Pancreatic Cancer
  • Gastric Cancer
  • Breast Cancer
  • Prostate Cancer
  • Lung Cancer
  • Others
Companies covered
  • Anergis
  • Antigen Express
  • Apitope Technology
  • Artificial Cell Technologies
  • Benovus Bio
  • Celgene Corporation
  • Immatics biotechnologies
  • ImmunoCellular Therapeutics
  • ISA Pharmaceuticals
  • Lytix Biopharma
  • OncoTherapy Science
  • Peptech
  • Pharmasyntez
  • Spotlight Innovation
  • Sumitomo Dainippon Pharma
  • TapImmune
  • Targovax
  • Merck

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Peptide Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Peptide Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Peptide Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Peptide Vaccine Market Dynamics
  1. 2.1 Peptide Vaccine Industry Trends
  2. 2.2 Peptide Vaccine Industry Drivers
  3. 2.3 Peptide Vaccine Industry Opportunities and Challenges
  4. 2.4 Peptide Vaccine Industry Restraints
3 Peptide Vaccine Market by Company
  1. 3.1 Global Peptide Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Peptide Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Peptide Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Peptide Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Peptide Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Peptide Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Peptide Vaccine Company Product Type and Application
  8. 3.8 Global Peptide Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Peptide Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Peptide Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Peptide Vaccine Market by Type
  1. 4.1 Peptide Vaccine Type Introduction
  2. 4.1.1 Solution Phase Synthesis (SPS)
  3. 4.1.2 Solid Phase Peptide Synthesis (SPPS)
  4. 4.2 Global Peptide Vaccine Sales Volume by Type
  5. 4.2.1 Global Peptide Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Peptide Vaccine Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Peptide Vaccine Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Peptide Vaccine Sales Value by Type
  9. 4.3.1 Global Peptide Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Peptide Vaccine Sales Value by Type (2021-2032)
  11. 4.3.3 Global Peptide Vaccine Sales Value Share by Type (2021-2032)
5 Peptide Vaccine Market by Application
  1. 5.1 Peptide Vaccine Application Introduction
  2. 5.1.1 Pancreatic Cancer
  3. 5.1.2 Gastric Cancer
  4. 5.1.3 Breast Cancer
  5. 5.1.4 Prostate Cancer
  6. 5.1.5 Lung Cancer
  7. 5.1.6 Others
  8. 5.2 Global Peptide Vaccine Sales Volume by Application
  9. 5.2.1 Global Peptide Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global Peptide Vaccine Sales Volume by Application (2021-2032)
  11. 5.2.3 Global Peptide Vaccine Sales Volume Share by Application (2021-2032)
  12. 5.3 Global Peptide Vaccine Sales Value by Application
  13. 5.3.1 Global Peptide Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  14. 5.3.2 Global Peptide Vaccine Sales Value by Application (2021-2032)
  15. 5.3.3 Global Peptide Vaccine Sales Value Share by Application (2021-2032)
6 Peptide Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Peptide Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Peptide Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Peptide Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Peptide Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Peptide Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Peptide Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Peptide Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Peptide Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Peptide Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Peptide Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Peptide Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Peptide Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Peptide Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Peptide Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Peptide Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Peptide Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Peptide Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Peptide Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Peptide Vaccine Sales Value Share by Country, 2025 VS 2032
7 Peptide Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Peptide Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Peptide Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Peptide Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Peptide Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Peptide Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Peptide Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Peptide Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Peptide Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Peptide Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Peptide Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Peptide Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Peptide Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Peptide Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Peptide Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Peptide Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Peptide Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Peptide Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Peptide Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Peptide Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Peptide Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Peptide Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Peptide Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Peptide Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Peptide Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Peptide Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Peptide Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Peptide Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Peptide Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Peptide Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Peptide Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Peptide Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Peptide Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Peptide Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Peptide Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Peptide Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Peptide Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Peptide Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Peptide Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Anergis
  2. 8.1.1 Anergis Company Information
  3. 8.1.2 Anergis Business Overview
  4. 8.1.3 Anergis Peptide Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Anergis Peptide Vaccine Product Portfolio
  6. 8.1.5 Anergis Recent Developments
  7. 8.2 Antigen Express
  8. 8.2.1 Antigen Express Company Information
  9. 8.2.2 Antigen Express Business Overview
  10. 8.2.3 Antigen Express Peptide Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Antigen Express Peptide Vaccine Product Portfolio
  12. 8.2.5 Antigen Express Recent Developments
  13. 8.3 Apitope Technology
  14. 8.3.1 Apitope Technology Company Information
  15. 8.3.2 Apitope Technology Business Overview
  16. 8.3.3 Apitope Technology Peptide Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Apitope Technology Peptide Vaccine Product Portfolio
  18. 8.3.5 Apitope Technology Recent Developments
  19. 8.4 Artificial Cell Technologies
  20. 8.4.1 Artificial Cell Technologies Company Information
  21. 8.4.2 Artificial Cell Technologies Business Overview
  22. 8.4.3 Artificial Cell Technologies Peptide Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Artificial Cell Technologies Peptide Vaccine Product Portfolio
  24. 8.4.5 Artificial Cell Technologies Recent Developments
  25. 8.5 Benovus Bio
  26. 8.5.1 Benovus Bio Company Information
  27. 8.5.2 Benovus Bio Business Overview
  28. 8.5.3 Benovus Bio Peptide Vaccine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Benovus Bio Peptide Vaccine Product Portfolio
  30. 8.5.5 Benovus Bio Recent Developments
  31. 8.6 Celgene Corporation
  32. 8.6.1 Celgene Corporation Company Information
  33. 8.6.2 Celgene Corporation Business Overview
  34. 8.6.3 Celgene Corporation Peptide Vaccine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Celgene Corporation Peptide Vaccine Product Portfolio
  36. 8.6.5 Celgene Corporation Recent Developments
  37. 8.7 Immatics biotechnologies
  38. 8.7.1 Immatics biotechnologies Company Information
  39. 8.7.2 Immatics biotechnologies Business Overview
  40. 8.7.3 Immatics biotechnologies Peptide Vaccine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Immatics biotechnologies Peptide Vaccine Product Portfolio
  42. 8.7.5 Immatics biotechnologies Recent Developments
  43. 8.8 ImmunoCellular Therapeutics
  44. 8.8.1 ImmunoCellular Therapeutics Company Information
  45. 8.8.2 ImmunoCellular Therapeutics Business Overview
  46. 8.8.3 ImmunoCellular Therapeutics Peptide Vaccine Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 ImmunoCellular Therapeutics Peptide Vaccine Product Portfolio
  48. 8.8.5 ImmunoCellular Therapeutics Recent Developments
  49. 8.9 ISA Pharmaceuticals
  50. 8.9.1 ISA Pharmaceuticals Company Information
  51. 8.9.2 ISA Pharmaceuticals Business Overview
  52. 8.9.3 ISA Pharmaceuticals Peptide Vaccine Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 ISA Pharmaceuticals Peptide Vaccine Product Portfolio
  54. 8.9.5 ISA Pharmaceuticals Recent Developments
  55. 8.10 Lytix Biopharma
  56. 8.10.1 Lytix Biopharma Company Information
  57. 8.10.2 Lytix Biopharma Business Overview
  58. 8.10.3 Lytix Biopharma Peptide Vaccine Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Lytix Biopharma Peptide Vaccine Product Portfolio
  60. 8.10.5 Lytix Biopharma Recent Developments
  61. 8.11 OncoTherapy Science
  62. 8.11.1 OncoTherapy Science Company Information
  63. 8.11.2 OncoTherapy Science Business Overview
  64. 8.11.3 OncoTherapy Science Peptide Vaccine Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 OncoTherapy Science Peptide Vaccine Product Portfolio
  66. 8.11.5 OncoTherapy Science Recent Developments
  67. 8.12 Peptech
  68. 8.12.1 Peptech Company Information
  69. 8.12.2 Peptech Business Overview
  70. 8.12.3 Peptech Peptide Vaccine Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Peptech Peptide Vaccine Product Portfolio
  72. 8.12.5 Peptech Recent Developments
  73. 8.13 Pharmasyntez
  74. 8.13.1 Pharmasyntez Company Information
  75. 8.13.2 Pharmasyntez Business Overview
  76. 8.13.3 Pharmasyntez Peptide Vaccine Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Pharmasyntez Peptide Vaccine Product Portfolio
  78. 8.13.5 Pharmasyntez Recent Developments
  79. 8.14 Spotlight Innovation
  80. 8.14.1 Spotlight Innovation Company Information
  81. 8.14.2 Spotlight Innovation Business Overview
  82. 8.14.3 Spotlight Innovation Peptide Vaccine Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Spotlight Innovation Peptide Vaccine Product Portfolio
  84. 8.14.5 Spotlight Innovation Recent Developments
  85. 8.15 Sumitomo Dainippon Pharma
  86. 8.15.1 Sumitomo Dainippon Pharma Company Information
  87. 8.15.2 Sumitomo Dainippon Pharma Business Overview
  88. 8.15.3 Sumitomo Dainippon Pharma Peptide Vaccine Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Sumitomo Dainippon Pharma Peptide Vaccine Product Portfolio
  90. 8.15.5 Sumitomo Dainippon Pharma Recent Developments
  91. 8.16 TapImmune
  92. 8.16.1 TapImmune Company Information
  93. 8.16.2 TapImmune Business Overview
  94. 8.16.3 TapImmune Peptide Vaccine Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 TapImmune Peptide Vaccine Product Portfolio
  96. 8.16.5 TapImmune Recent Developments
  97. 8.17 Targovax
  98. 8.17.1 Targovax Company Information
  99. 8.17.2 Targovax Business Overview
  100. 8.17.3 Targovax Peptide Vaccine Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Targovax Peptide Vaccine Product Portfolio
  102. 8.17.5 Targovax Recent Developments
  103. 8.18 Merck
  104. 8.18.1 Merck Company Information
  105. 8.18.2 Merck Business Overview
  106. 8.18.3 Merck Peptide Vaccine Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Merck Peptide Vaccine Product Portfolio
  108. 8.18.5 Merck Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Peptide Vaccine Value Chain Analysis
  2. 9.1.1 Peptide Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Peptide Vaccine Sales Mode & Process
  6. 9.2 Peptide Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Peptide Vaccine Distributors
  9. 9.2.3 Peptide Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst